{"prompt": "['5.3 Laboratory Measurements', 'Blood tests will be completed at screening if needed for determining eligibility. Blood for metabolic research studies', 'will be obtained at baseline (Cycle 0, Day 1), and Cycles 6, 12, and 24 (Table 1). Complete details on sample', 'collection and shipment procedures for research samples can be found in SOM: Appendices 17-19.', 'Investigators may have additional blood tests performed for the purpose of planning treatment administration,', 'dose modification, or following adverse events.', '5.3.1 Haematology/Blood Chemistry', 'These tests are typically standard of care (SOC) for this patient population. The clinical research coordinator will', 'record these and any other assessments ordered by the MD not pertaining directly to the study assessments', 'throughout the study period, when available.', 'Haemoglobin', 'Platelet count', 'Red blood cell count', 'White blood cell count', 'White blood cell differential', 'Total bilirubin (if >1.5 X ULN, include analysis of direct and indirect bilirubin)', 'Alanine transaminase (ALT)', 'Aspartate transaminase (AST)', 'Alkaline phosphatase (ALP)', 'Albumin', 'Sodium', 'Potassium', 'Calcium (serum)', 'Magnesium', 'Blood urea nitrogen (BUN) or urea', 'Creatinine', 'Glucose', 'Lactate Dehydrogenase (LDH)', 'Prostate specific antigen (PSA)', 'Testosterone', 'Sites may perform additional local haematology and/or blood chemistry assays for the purposes of planning', 'therapy administration, therapy dose modification, or monitoring adverse events.', '5.3.2 Clinical Requests', 'Fasting Lipid profile (HDL, LDL, and Triglycerides), fasting glucose, and HbA1c will be requested at local sites', 'at baseline and Cycle 6. Halabi measurements (PSA, LDH, albumin, haemoglobin and ALP) will be requested', 'at local sites at screening (part of eligibility criteria) and cycles 6 and 12.', '5.3.3 Additional blood markers', 'Interleukin-1 beta (IL-1B), IL-6, TNFa, Interleukin-2 (IL-2), adiponectin, c-peptide, insulin, sex hormone binding', 'globulin', '(SHBG),', \"CRP and IGF-1 will be performed for time point's baseline and Cycle 6. Testosterone,\", 'dihydrotestosterone, androstenedione, DHEA, 17-hyroxypreogesterone, 17-hydroxypregnenolone, and', 'progesterone will be assessed at baseline only.', '5.3.4 Diagnostic archived tumour specimens', 'Consent to obtain archived prostate cancer tumour samples or slides will be requested from all participants.', '5.4', 'Questionnaire Data', 'INTERVAL Protocol Version 4.0, 19 April 2018', '23']['Patients will complete these forms within 28 days prior to the screening CPET and 7 days prior to Day 1 of', 'Cycle 3, 6, 9, 12, 15, 18, 21, 24, and then on a yearly basis. (See Table 1. Summary of Assessments). Dietary', 'intake will be assessed prior to the screening CPET and 7 days prior to Day 1 of Cycle 12 and 24.', 'Questionnaires to be completed will include:', 'Brief-Pain Inventory Short Form (BPI-SF): (screening, cycles 6,12,18 and 24) Appendix 20) A 9-', 'item tool used to assess the severity of pain and the impact of pain on activities of daily living over a', \"recall period of 24 hours. Pain severity is assessed across four sub-scales; 'worst pain', 'least pain',\", '\"average pain\\' and \\'current pain\\'. A pain score for each subscale is presented separately. Scales are', 'rated on a scale of 0 to 10 (0 = no pain; 10 = pain as bad as one can imagine). A composite score for', 'pain severity is calculated as the mean of the four severity items. Question 9 comprises a 7-item', 'interference scale. Questions assess the level to which pain interferes with general activity, walking,', 'work, mood, enjoyment of life, relations with others and sleep on a scale of 0 to 10 (0 = does not', 'interfere; 10 = completely interferes). Mean interference score will be calculated as an average of the', 'seven subparts of question 9 where at least four of the seven items are completed. The BPI-SF can', 'be completed in 10 minutes.', 'Functional Assessment of Cancer Therapy-Prostate (FACT-G): (Appendix 21) The FACT-G', 'consists of 27-items. We will be assessing the social/family wellbeing domain of the FACT-G only,', 'while the full EORTC QLQ-C30 will be the primary QOL assessment (described below). This can be', 'completed in 5 minutes.', 'Expanded Prostate Cancer Index Composite (EPIC-26): (Appendix 22) The EPIC questionnaire', 'focuses on 5 domains: urinary incontinence and irritation, bowel, sexual, and hormonal, with function-', 'specific bother in each domain. Resulting domain scores for the EPIC-26 is on a 0 to 100 scale; higher', 'values representing a more favourable HRQOL. Complete reliability and validity evaluations were', 'conducted for EPIC and are previously described.46', 'Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale:', '(Appendix 23) The FACIT-fatigue subscale contains 13-items assessing the consequences of fatigue.', 'Each item is rated on a 5-point Likert scale ranging from 0 = not at all to 4 = very much. The FACIT-', '-', 'Fatigue can be completed in 5 minutes.', 'EuroQOL 5-dimension questionnaire (EQ-5D): (screening, cycles 6, 12, 18 and 24) (Appendix', '24) The EQ-5D evaluates the health state of an individual. The questionnaire assesses health related', 'QOL across five socially relevant domains: i) mobility, ii) self-care, iii) usual activities, iv) pain-', 'discomfort, and v) anxiety-depression. Participants must grade their own current level of function in', 'each domain according to three levels of disability (severe, moderate or none). Furthermore,', 'participants self-assess their own health status on an accompanying visual analogue scale (VAS)', 'ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Value sets are', 'used to weight each of the 245 health states that can be ranked and transformed to a single utility', 'score. The utility score is an expression of Quality Adjusted Life Years (QALY). A QALY places a', 'weight on time in different health states, providing a composite score of life expectancy and quality of', 'remaining years and is therefore a measure of quality of life adjusted survival. The most recent five-', 'level version (EQ-5D-5L) will be used. The EQ-5D-5L can be completed in 10 minutes.', 'EORTC QLQ-C30: (Appendix 25) The EORTC QLQ-C30 consists of 30 questions developed to', 'assess the quality of life of cancer patients. It incorporates nine multi-item scales: five functional', 'scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and', 'nausea and vomiting); and a global health and quality-of-life scale. Several single-item symptom', 'measures are also included. The QLC-C30 was designed to be cancer-specific, multidimensional in', 'structure, appropriate for self-administration, and applicable across a range of cultural settings.', 'INTERVAL Protocol Version 4.0, 19 April 2018', '24']\n\n###\n\n", "completion": "END"}